David Tougeron - Publications

Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: July 03, 2026

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).

Journal: Future oncology (London, England)

Published: May 11, 2026

Interpretable AI to predict anal cancer local failure at 3 years with the FFCD Anabase prospective multicentric cohort.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: April 22, 2026

Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 22, 2026

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 18, 2026

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2026

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 07, 2026

FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 03, 2026

Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 24, 2026

Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆.

Journal: ESMO open

Published: February 17, 2026

Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.

Journal: The oncologist

Published: February 10, 2026

Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study).

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026